Sector revisions Roche Holding AG

Equities

End-of-day quote Swiss Exchange Other stock markets 2026-06-05			5-day change	1st Jan Change
327.10 ^CHF	+0.77%		-0.67%	-0.34%

07:32pm	Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial	RE
Jun. 05	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	ROCHE HOLDING AG							17
	ELI LILLY AND COMPANY							29
	JOHNSON & JOHNSON							23
	ABBVIE INC.							29
	ASTRAZENECA PLC							21
	NOVARTIS AG							21
	NOVO NORDISK A/S							23
	AMGEN INC.							30
	GILEAD SCIENCES, INC.							29
	PFIZER INC.							27
	BRISTOL-MYERS SQUIBB COMPANY							25
	VERTEX PHARMACEUTICALS INCORPORATED							29
	SANOFI							23
	GSK PLC							20
	CHUGAI PHARMACEUTICAL CO., LTD.							15
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							15
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							16
	BAYER AG							19
	ALNYLAM PHARMACEUTICALS, INC.							27
	TEVA PHARMACEUTICAL INDUSTRIES LIMITED							11
	Average							22
	Weighted average by Cap.							25